ADE, I Hardly Knew Ye
EPR3 and Me (and Updates)
The Midas Touch
COPD Therapeutics: Does This Work?
"I Know How to Use My Inhaler"
100
Rinsing one's mouth after using ICS reduces the incidence
Oropharnygeal candidasis (thrush)
100
FDA-approved LAMA for asthma
Spiriva Respimat
100
GOLD 1 classification indicates an FEV1 >/= ____ than predicted
80%
100
A narrow therapeutic index drug no longer recommended as part of routine chronic COPD management
Theophylline (methylxanthines)
100
This is a process performed prior to initial use or after extended disuse of an MDI
Priming
200
Levalbuterol is purported to less frequently cause this compared to racemic albuterol
Tachycardia
200
Guideline-studied SMART therapy inhaler combination
Budesonide/formoterol (Symbicort)
200
These two scales measure symptom severity with COPD
mMRC dyspnea scale and CAT
200
Triple therapy with this combination inhaler improves lung function and symptoms while reducing exacerbation compared to dual therapy (name 1)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate)
200
Decreased inspiratory flow with disease progression may make this inhaler type potentially more useful and easy to use for a patient
Soft mist inhaler (e.g., Respimat)
300
These two monoclonal treatments carry a BBW for anaphylaxis (name 1)
Omalizumab (Xolair) or rezlizumab (Cinqair)
300
Initial asthma severity classification for adult with 3 days/week symptoms and nighttime awakenings of 3x a month
Mild persistent
300
A class of treatment suitable for Groups B, C, and D of COPD
LAMA
300
Once daily or three times weekly use of this macrolide for 1 yr can reduce COPD exacerbation rates compared to usual management
Azithromycin (Zithromax)
300
A counseling point for a DPI like Seebri Neohaler (glycopyrrolate)
1. Do not block air inlet
2. Breath in deep and fast
3. Avoid keeping in moist or wet environment
400
While an FDA advisory panel did not find increased risk of neuropsychiatric adverse events, the FDA upgraded this drug's warning for it to a BBW in 2020
Montelukast (Singulair)
400
Initial asthma severity classification for daily SABA use (not for EIB)
Moderate persistent
400
Patients with 1 exacerbation (no hospitalization) and a CAT=12 qualify for what initial therapy class (name 1)
LABA or LAMA
400
Very severe COPD patients with chronic bronchitis can benefit from this oral PDE4 inhibitor
Roflumilast (Daliresp)
400
Valved holding chamber (spacer)
500
Concomitant use of montelukast and this class of drug may lead to severe peripheral edema due to drug interactions
Oral corticosteriods
500
An add-on therapy for severe persistent asthma with allergies
Omalizumab (Xolair)
500
Exacerbation with blood eosinophils >300 cells/mL is an indication to start this type of therapy
Inhaled corticosteroids (ICS)
500
Frequent pneumonia hospitalizations are a reason to stop this particular component of inhaler therapy for COPD
Inhaled corticosteroids (ICS)
500
Ellipta device